Our Science
We believe there is a treatment available for every rare genetic disease, we just need to find it!
MODELIS DOES DRUG DISCOVERY DIFFERENTLY
Leveraging our in vivo drug discovery platform, data, machine learning, and simple animal models, we focus on unlocking Mechanism of Actions for rare and complex genetic disorders with unmet needs, where traditional approaches to drug discovery aren’t practical and feasible.
OUR APPROACH IS SAVING TIME AND MONEY
We leverage biology and AI/ML to utilize an innovative platform approach to remove the cost and time barriers present in the traditional approach. This means better drug candidates and faster drug discovery.
HOW WE DO IT AND WHY IS IT UNIQUE
We leverage ML–enabled data processing, analyze biological data, and learn from the results to uncover insights about disease pathologies. We perform phenotype-based screening, looking for any molecules that improve symptoms overall, independent of the molecule’s potential role in a mechanism of action. Further, we perform all early drug discovery steps in vivo, utilizing multiple, complementary simple animal models to encapsulate the complexity of diseases and leveraging them to combine hit discovery, hit-to-lead, and lead optimization steps within vivo studies.
LEVERAGING SIMPLE MODELS
Did you know 80% of the genes causing human diseases are evolutionarily conserved in worms and fish?
We are the only company using small-animal in vivo models for drug discovery to streamline insight identification and validation. We use simple animal models because of their biological relevance, ease of use and convenience, and biological and organismal complexity.
PHENOTYPE-BASED SCREENING
Phenotypic drug discovery isn’t new; it’s proven and successful. Our unbiased phenotype-based screening approach utilizes in vivo, high-throughput screening to identify compounds with high translational potential. We have access to a diversified library with an exclusive mix of private and public molecules that are proven safe.
BROADENING THE SPOTLIGHT OF DRUG DISCOVERY
Our approach broadens the scope of data collection and analysis, increasing the likelihood of breakthroughs and finding new treatments. Traditional drug discovery approaches narrow the focus on specific therapeutic targets at a molecular level, lowering the chance for breakthroughs discoveries.
MECHANISM OF ACTION
Our unbiased phenotype-based screening approach allows identification of new mechanisms of action that would not have been thought to be involved in the studied disease via a classical, target-based approach. Modelis initiates in vivo functional assays to validate the mechanism of action of the lead candidate molecule (see below). Leveraging the genetic and pharmacological accessibility of our small model organisms, we confirm the implication of the known molecular target(s) of the hit molecule in a new context of the disease studied.
HARNESS THE POWER OF DATA WITH ARTIFICIAL INTELLIGENCE
We are building an in vivo-leveraged, AI-driven data platform uncovering mechanisms of action for complex rare, genetic diseases to find better therapies, faster.
Today, Modelis is uniquely positioned to find new therapies and generating our own insights into our target diseases. We are also looking to develop proprietary assets and chemistry for our internal pipeline, while leveraging partnerships and networks to feed the platform to drive ongoing insight development
OUR PARTNERS
Our combined resources with best-in-class partners and network collaborators drive research with meaningful impact.
OUR PIPELINE
We are currently advancing rapid-development programs to treat seven rare diseases, four backed by venture philanthropists.
Modelis does research differently
Our research leverages small animal models to test existing drugs to see how they effect genetic diseases. Thanks to their small size, worms and fish are central in Modelis’ process to offering a fast and cost-friendly approach for patients and partners.
We leverage simple models
Did you know that 80% of the genes causing human diseases are evolutionarily conserved in fish and worms? Humans, fish, and worms have a lot in common, which is why Modelis leverages these animals to iteratively repurpose existing treatments in a fast and cost-friendly way.
We broaden the spotlight of drug discovery
Traditional drug discovery approaches have narrowed the focus on specific therapeutic targets at a molecular level. This approach is high risk with a lower chance of breakthroughs because it may be missing the potential cure. Modelis’ approach broadens the scope of molecules tested which increases the likelihood of finding new treatments.
We are creating strategic partnerships
We are partnering with genetic sequencing centres, biotech and pharmaceutical companies to accompany families in their diagnostic journey and further expand the number of molecules available for testing.
Previous
Next
See our research at work
Patients become partners as we move towards finding a cure for their rare genetic disease.
©2022 Modelis inc. All rights reserved